News
Memo Therapeutics AG Antibodies Against SARS-CoV-2 Show Efficacy Against British and South African Variant
Memo Therapeutics AG, an innovator in the field of antibody discovery and development, announced today that MTX-COVAB, its human-derived antibody against SARS-CoV-2, the virus that causes COVID-19, has shown efficacy against both the original virus as well as the...
News
Sharp Appoints New Leader to its Global Clinical Services Business
Sharp, a part of UDG Healthcare and a leading provider of pharmaceutical packaging and clinical services, has appointed Robert O’Beirn as SVP and Managing Director of its global Clinical Services business.
Mr O’Beirn joined UDG Healthcare ten years ago as...
News
LANXESS India continues to support fight against COVID-19 through its CSR initiatives
LANXESS India has committed over INR 2.1 crores as part of its CSR spends to support the medical infrastructure in the country in its fight against the Coronavirus pandemic. The spike in COVID-19 cases in the second wave has...
Drug Research
Dr. Reddy’s Laboratories enters into a Voluntary Licensing Agreement with Lilly to Expand Access to COVID-19 Treatment in India
Dr. Reddy's Laboratories Ltd. announced that it has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company ("Lilly") for the manufacture and commercialization of the drug, baricitinib, in India.
The drug baricitinib has received restricted emergency...
News
Parexel Achieves Top Rankings in Industry Across Multiple Attributes in ISR CRO Phase II-III Benchmarking Report
Parexel, a leading provider of solutions to accelerate the development and delivery of innovative new therapies to improve world health, announced the company has been ranked first among global Clinical Research Organizations (CROs) for Customer Loyalty and in the...
News
MedPharm Expands Its Formulation Development Labs in the UK
MedPharm Ltd, the world leader in formulation and development services for topical and transdermal products, has announced a £1.5M refurbishment that will increase laboratory space in the UK by 30%.
The renovations will incorporate increased investment in automated technologies to...
Clinical Trials
Bharat Biotechs Covaxin approved for phase 2/3 trials on children
The Drugs Controller General of India (DGCI) has approved Bharat Biotech's COVID-19 vaccine Covaxin for phase II/III clinical trial on those aged between two to 18 years. The trial will take place in 525 subjects at various sites, including...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read